| 产品描述: | KU-60019是一种改进的KU-55933类似物,在无细胞试验中作用于ATM,IC50为6.3 nM,作用于ATM比作用于DNA-PK和ATR的选择性分别高270和1600倍,并且是高度有效的放射增敏剂 |
| 靶点: |
ATM(Cell-free assay):6.3 nM;ATM/ATR |
| 体内研究: |
In orthotopic glioma U1242/luc-GFP xenograft models, the combination of KU-60019 and radiation significantly increases survival of mice than KU-60019 alone, radiation alone, or no treatment. In addition, p53-mutant gliomas is much more sensitive to KU-60019 radiosensitization than wild-type glioma |
| 细胞实验: |
Cell lines: U87和U1242 Concentrations: 溶于水,终浓度为~3 μM Incubation Time: 1, 3, 和5天 Method: 使用KU-60019处理细胞1, 3,和 5天。通过AlamarBlue测定细胞生长。AlamarBlue加到培养基中,达到推荐的最终浓度。实验板在37oC下温育1小时,在Fluoro-Count酶标仪上(激发光530 nm,发射光590 nm)测定荧光值, 测定结果昨晚衡量细胞生长的一个指标。通过台酚蓝/荧光激活的细胞分选(FACS)实验测定细胞存活。 |
| 动物实验: |
Animal Models: Athymic female mice harboring orthotopic glioma U1242/luc-GFP tumors or human glioma U1242/luc-GFP tumors Dosages: KU-60019 (10 μM) is delivered at a rate of 0.5 μL/h by osmotic pump; KU-60019 (250 μM) in 12.5 μL is infused by CED. Administration: Administered intratumorally by convection-enhanced delivery or osmotic pump |
| 参考文献: |
1. Golding SE, et al. Mol Cancer Ther, 2009, 8(10), 2894-2902. 2. Clin Cancer Res. 2013, 19(12), 3189-3200. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.826 ml |
9.129 ml |
18.259 ml |
| 5 mM |
0.365 ml |
1.826 ml |
3.652 ml |
| 10 mM |
0.183 ml |
0.913 ml |
1.826 ml |
| 50 mM |
0.037 ml |
0.183 ml |
0.365 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |